Department of Surgery, New York University Grossman School of Medicine and NYU-Langone Health, New York, NY.
VA New York Harbor Healthcare System, New York, NY.
Ann Surg. 2023 Nov 1;278(5):e1073-e1079. doi: 10.1097/SLA.0000000000005827. Epub 2023 Feb 22.
We aimed to determine whether surgeon variation in management of intraductal papillary mucinous neoplasm (IPMN) is driven by differences in risk perception and quantify surgeons' risk threshold for changing their recommendations.
Surgeons vary widely in management of IPMN.
We conducted a survey of members of the Americas HepatoPancreatoBiliary Association, presented participants with 2 detailed clinical vignettes and asked them to choose between surgical resection and surveillance. We also asked them to judge the likelihood that the IPMN harbors cancer and that the patient would have a serious complication if surgery was performed. Finally, we asked surgeons to rate the level of cancer risk at which they would change their treatment recommendation. We examined the association between surgeons' treatment recommendations and their risk perception and risk threshold.
One hundred fifty surgeons participated in the study. Surgeons varied in their recommendations for surgery [19% for vignette 1 (V1) and 12% for V2] and in their perception of the cancer risk (interquartile range: 2%-10% for V1 and V2) and risk of surgical complications (V1 interquartile range: 10%-20%, V2 20-30%). After adjusting for surgeon characteristics, surgeons who were above the median in cancer risk perception were 22 percentage points (27% vs 5%) more likely to recommend resection than those who were below the median (95% CI: 11%-4%; P <0.001). The median risk threshold at which surgeons would change their recommendation was 15% (V1 and V2). Surgeons who recommended surgery had a lower risk threshold for changing their recommendation than those who recommended surveillance (V1: 10.0 vs 15.0, P =0.06; V2: 7.0 vs 15.0, P =0.05).
The treatment that patients receive for IPMNs depends greatly on how their surgeons perceive the risk of cancer in the lesion. Efforts to improve cancer risk prediction for IPMNs may lead to decreased variations in care.
我们旨在确定外科医生在处理导管内乳头状黏液性肿瘤(IPMN)方面的管理差异是否是由风险感知的差异驱动的,并量化外科医生改变其建议的风险阈值。
外科医生在 IPMN 的治疗管理上存在很大差异。
我们对美洲肝胆胰协会的成员进行了一项调查,向参与者展示了 2 个详细的临床病例,并要求他们在手术切除和监测之间做出选择。我们还要求他们判断 IPMN 是否存在癌症的可能性以及手术会给患者带来严重并发症的可能性。最后,我们要求外科医生对他们会改变治疗建议的癌症风险水平进行评分。我们研究了外科医生的治疗建议与其风险感知和风险阈值之间的关系。
共有 150 名外科医生参与了这项研究。外科医生对手术的建议各不相同[病例 1(V1)为 19%,病例 2(V2)为 12%],对癌症风险(V1 中位数范围:2%-10%,V2 中位数范围:2%-10%)和手术并发症风险(V1 中位数范围:10%-20%,V2 中位数范围:20%-30%)的感知也各不相同。在调整外科医生特征后,癌症风险感知高于中位数的外科医生比低于中位数的外科医生更有可能推荐手术切除,差异为 22 个百分点(27%比 5%)(95%CI:11%-4%;P <0.001)。外科医生会改变其建议的风险阈值中位数为 15%(V1 和 V2)。建议手术的外科医生改变其建议的风险阈值低于建议监测的外科医生(V1:10.0 比 15.0,P =0.06;V2:7.0 比 15.0,P =0.05)。
患者接受的 IPMN 治疗在很大程度上取决于其外科医生对病变癌症风险的感知。努力提高 IPMN 的癌症风险预测能力可能会减少治疗上的差异。